299 related articles for article (PubMed ID: 28506524)
1. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
[TBL] [Abstract][Full Text] [Related]
3. Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer.
Alanee S; Moore A; Nutt M; Holland B; Dynda D; El-Zawahry A; McVary KT
Anticancer Res; 2015 Jul; 35(7):4145-50. PubMed ID: 26124369
[TBL] [Abstract][Full Text] [Related]
4. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
5. Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study.
Wang J; Liu X; Wang Y; Ren G
Cancer Med; 2019 Nov; 8(15):6799-6806. PubMed ID: 31518071
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
[TBL] [Abstract][Full Text] [Related]
9. Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.
Metzger AL; Abel S; Wegner RE; Fuhrer R; Mao S; Miller R; Beriwal S; Horne ZD
Prostate; 2019 Sep; 79(12):1457-1461. PubMed ID: 31294484
[TBL] [Abstract][Full Text] [Related]
10. A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer.
Syed S; Basourakos SP; Ali FS; Garcia JL; Zurita-Saavedra A; Gong Z
Am J Clin Oncol; 2020 Feb; 43(2):87-93. PubMed ID: 31764016
[TBL] [Abstract][Full Text] [Related]
11. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study.
Knipper S; Preisser F; Mazzone E; Mistretta FA; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2019 Jun; 17(3):231-237.e2. PubMed ID: 31080021
[TBL] [Abstract][Full Text] [Related]
12. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study.
Deorah S; Rao MB; Raman R; Gaitonde K; Donovan JF
BJU Int; 2012 Mar; 109(6):824-30. PubMed ID: 21883857
[TBL] [Abstract][Full Text] [Related]
14. Laryngeal Neuroendocrine Carcinoma: A Population-Based Analysis of Incidence and Survival.
Ghosh R; Dutta R; Dubal PM; Park RC; Baredes S; Eloy JA
Otolaryngol Head Neck Surg; 2015 Dec; 153(6):966-72. PubMed ID: 26183520
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
Front Oncol; 2020; 10():571308. PubMed ID: 33598420
[TBL] [Abstract][Full Text] [Related]
16. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
17. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
18. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
19. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses.
Lin LM; Lin Q; Liu J; Chu KX; Huang YX; Zhang ZK; Li T; Dai YQ; Li JL
Cancer Med; 2020 Sep; 9(18):6524-6532. PubMed ID: 32705800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
